Replimune Group, Inc.: GOLDMAN SACHS GROUP INC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Goldman Sachs Group Inc. filed an amended Schedule 13G with the SEC (accession 0000886982-26-000560) updating its ownership stake in Replimune Group, Inc. The amendment discloses a change to the bank's previously reported passive position in the clinical-stage biotech, though the filing summary did not specify the revised share count or percentage. The update matters because 13G amendments signal shifts in large institutional holdings that can influence Replimune's float and investor sentiment. Investors will watch for the detailed filing to confirm whether Goldman's stake rose or fell and at what size.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Goldman Sachs Group Inc. (GS), Replimune Group, Inc.
A linked name opens that asset's sentiment page.